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Abstract: Changes in fetal DNA methylation (DNAm) of the leptin (LEP) gene have been associated
with exposure to maternal hyperglycemia, but their links with childhood obesity risk are still
unclear. We investigated the association between maternal hyperglycemia, placental LEP DNAm
(25 5′-C-phosphate-G-3′ (CpG) sites), neonatal leptinemia, and adiposity (i.e., BMI and skinfold
thickness (ST) (subscapular (SS) + triceps (TR) skinfold measures, and the ratio of SS:TR) at 3-years-old,
in 259 mother–child dyads, from Gen3G birth cohort. We conducted multivariate linear analyses
adjusted for gestational age at birth, sex of the child, age at follow-up, and cellular heterogeneity.
We assessed the causal role of DNAm in the association between maternal glycemia and childhood
outcomes, using mediation analysis. We found three CpGs associated with neonatal leptinemia
(p ≤ 0.002). Of these, cg05136031 and cg15758240 were also associated with BMI (β = −2.69, p = 0.05)
and fat distribution (β = −0.581, p = 0.05) at 3-years-old, respectively. Maternal glycemia was
associated with DNAm at cg15758240 (β = −0.01, p = 0.04) and neonatal leptinemia (β = 0.19,
p = 0.004). DNAm levels at cg15758240 mediates 0.8% of the association between maternal glycemia
and neonatal leptinemia (p < 0.001). Our results support that DNAm regulation of the leptin pathway
in response to maternal glycemia might be involved in programming adiposity in childhood.
Keywords: childhood obesity; skinfolds thickness; BMI; epigenetics; fetal programming; maternal
hyperglycemia; pregnancy
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1. Introduction
Childhood obesity is a growing public health problem [1]. It has been linked to various
comorbidities, including type 2 diabetes, asthma, dyslipidemia, and psychosocial disorders, which
have been increasing recently [2]. In addition, offspring with obesity are likely to remain obese
in adulthood, increasing the risk for the perpetuation of a vicious cycle, leading to obesity [3,4].
Thus, it is critical to identify the mechanisms involved in the pathogenesis of childhood obesity,
and more specifically in the context of studies on the Developmental Origin of Health and Disease
(DOHaD) hypothesis.
The DOHaD hypothesis postulates that exposure to adverse maternal environment during
early development is associated with later onset of numerous chronic disorders over the life course,
including obesity [5–9]. Plasticity of the epigenome combined with high rate of cellular divisions
and differentiations, and also strong DNA methyltransferases (DNMTs) activity during embryonic
and fetal development may be part of the molecular mechanisms implicated in DOHaD [10,11].
DNA methylation (DNAm), the most studied epigenetic modification, has been identified among the
potential underlying mechanisms involved in the regulation of many metabolic functions, including
leptin (LEP) gene expression regulation in the placenta [12–14]. Indeed, the placenta has been suggested
as a relevant tissue in the field, as it plays a crucial role in materno–fetal exchanges optimizing fetal
growth, influences maternal physiology by secreting hormones (e.g., leptin), and has on average
lower DNAm levels, suggesting that many genes are actively transcribed to support its metabolic
activity [15–17].
Leptin, a hormone mainly secreted by white adipocytes, but also by the placenta, is a key
player in the regulation of energy expenditure [18]. Leptin inhibits the hypothalamic stimuli for food
intake and therefore is highly suspected to be a risk factor for obesity and insulin resistance when
deregulated [19,20]. We have shown before that maternal hyperglycemia is associated—and may be
causally implicated—with changes in neonatal offspring DNAm levels at the leptin gene (LEP) [21].
However, whether these variations in DNAm at the LEP gene locus are linked to future risk of obesity
is still unknown. Therefore, we hypothesized that placental DNAm variations at the LEP gene locus
contribute to the programming of abnormal fat accretion in childhood in response to maternal glucose
metabolism changes in pregnancy.
2. Results
2.1. Sample Characteristics
Characteristics (mean ± SD) of the 262 mothers–child dyads are shown in Table 1. Briefly, on
average, mothers’ age was 28.2 ± 4.3-years-old and had an early pregnancy Body mass index (BMI)
of 25.4 ± 5.7 kg/m2. Gestational age at birth was 39.6 ± 1.0 weeks, with a birthweight of 3.4 ± 0.4 kg.
At follow-up, children were aged 40.5 ± 3.0 months and had a BMI of 16.3 ±1.9 kg/m2. The sum (Σ)
and ratio (suprascapular (SS): tricipital (TR)) of skinfold thickness (ST) were 17.5 ± 4.1 mm and 0.6
± 0.2 respectively. We observed positive correlations between childhood BMI z-scores and skinfold
measures (ΣST: r = 0.49 p < 0.001; and SS:TR: r = 0.11, p = 0.03) at 3-years-old. Birthweight was
associated with cord blood leptinemia (r = 0.33, p < 0.001), as well as weight (r = 0.33; p < 0.001) and
BMI z-score (r = 0.22; p < 0.001) at 3 years old but not with any of the two ST measures (ΣST: r = 0.01;
p = 0.91, SS:TR: r = 0.04; p = 0.50). Maternal fasting glucose levels measured at the second trimester
of pregnancy were associated with cord blood leptinemia (β = 0.19, p = 0.004) after adjustment for
maternal age and BMI at the first trimester of pregnancy, gestational age at delivery, and sex of the
offspring. Alone, second-trimester maternal fasting glucose levels explain 2.7% of the neonatal leptin
levels variance (p = 0.009). Maternal glycemia during pregnancy was not significantly associated with
any of the adiposity markers (i.e., BMI z-scores: r = −0.03, p = 0.62; ΣST: r = 0.04, p = 0.53; and SS:TR:
r = 0.11, p = 0.09) measured at 3-years-old
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Table 1. Clinical characteristics of the mother–child dyads from the Genetics of Glucose regulation in
Gestation and Growth (Gen3G) cohort.
Participant Clinical Data n = 262 Mean ± SD
Maternal characteristics
1st trimester of pregnancy
Age (years) 28.6 ± 4.2
BMI (kg/m2) 25.5 ± 5.5
Smoking during pregnancy
Yes 7.4%
No 91.8%
Glucose 1 h post 50 g GCT (mmol/l) 5.0 ± 2.2
2nd trimester of pregnancy
Fasting Glucose (mmol/L) 4.2 ± 0.3
Glucose 2 h post 75 g OGTT (mmol/L) 5.9 ± 1.4
Child characteristics
At birth
Gestational age at birth (weeks) 39.6 ± 1.0
Sex
Boys 55%
Girls 45%
Birthweight (kg) 3.4 ± 0.4
Cord blood leptin levels (ng/mL) 15,028 ± 12,791
At 3-years-old
Age (months) 40.5 ± 3.0
Weight (kg) 15.2 ± 1.7
BMI (kg/m2) 16.1 ± 1.2
BMI z-scores 0.5 ± 0.9
Sum of skinfolds thicknesses (mm)α 17.5 ± 3.6
Ratio of skinfold thicknesses (SS:TR)α 0.6 ± 0.1
BMI: Body mass index; GCT: glucose challenge test; OGTT; OGTT: Oral glucose tolerance test; SS: Suprascapular;
TR: Tricipital. n = 259.
2.2. Identification of Potential Functional LEP 5′-C-phosphate-G-3′ (CpG) Sites and Association with
Childhood Anthropometric Profile
We prioritized CpG sites more likely to have a regulatory role on cord blood leptinemia based
on the correlation between DNAm levels and cord blood leptinemia. After Bonferroni correction for
multiple testing for nine independent CpG sites or regions (i.e., highly intercorrelated CpGs; significant
at p < 0.006), methylation levels cg15758240 (r = −0.29, p < 0.001), cg05136031 (r = 0.22, p < 0.001), and
cg23381058 (r = −0.20, p = 0.002) were significantly associated with cord blood leptin levels and thus
retained for further analyses (Table 2). We then tested associations between DNAm between these
three CpG sites and childhood-adiposity-related measures (Table 3). DNAm levels at cg05136031 were
associated with BMI z-scores (β = −2.69, p = 0.05), whereas those at cg15758240 were associated with
SS:TR (β = −0.581, p = 0.05) at 3 years of age (Figure 1).
Table 2. Correlations between placental Leptin (LEP) DNA methylation levels and cord blood leptinemia.
CpG Sites from the MethylationEPIC BeadChip Cord Blood Leptin Levels
cg15758240 r = −0.289p < 0.001
cg00011113 r = −0.141p = 0.03
cg05136031 r = 0.221p < 0.001
Int. J. Mol. Sci. 2020, 21, 329 4 of 13
Table 2. Cont.
CpG Sites from the MethylationEPIC BeadChip Cord Blood Leptin Levels
Mean for cg12782180, cg19594666, cg11045943,
cg26814075, cg13381984
r = −0.125
p = 0.05
cg00666422 r = −0.129p = 0.04
cg20564991 r = −0.061p = 0.34
cg23381058 r = −0.198p = 0.002
cg18603538 r = 0.006p = 0.93
cg04833007 r = −0.045p = 0.48
Cpg: 5′-C-phosphate-G-3′. Results statistically significant after Bonferroni adjustment (p < 0.05/9 = 0.006).
Table 3. Associations between placental LEP DNA methylation levels and markers of childhood
adiposity.
CpG Sites BMI z-Scores Sum of Skinfold Thickness Ratio of Skinfold Thickness
cg15758240 β = −0.391p = 0.82
β = 9.076
p = 0.21
β = −0.581
p = 0.05
cg05136031 β = −2.687p = 0.05
β = −1.441
p = 0.80
β = −0.083
p = 0.72
cg23341058 β = 0.019p = 0.62
β = 3.407
p = 0.35
β = 0.015
p = 0.92
The sum of skinfold thickness was computed with SS + TR, whereas the ratio is SS:TR. Significant results when
p ≤ 0.05. All models were adjusted for gestational age at delivery, sex of the offspring, age at follow-up, and
cellular heterogeneity.
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Figure 1. Associations between placental LEP DNA methylation (DNAm) and childhood adiposity. 
Linear regressions were applied to assess the relation between LEP DNAm levels at (A) cg05136031 
and BMI z-scores; and (B) cg15758240 and the skinfold thickness ratio (SS:TR), a marker of fat 
distribution. All p-values are adjusted for gestational age at delivery, sex of the offspring, age at 
follow-up (for skinfold thicknesses) and cell-types composition using ReFACTor. DNAm levels are 
shown between 0 and 1. 
  
Figure 1. Associations between placental LEP DNA methylation (DNAm) and childhood adiposity.
Linear regressions were applied to assess the relation between LEP DNAm levels at (A) cg05136031 and
BMI z-scores; and (B) cg15758240 and the skinfold thickness ratio (SS:TR), a marker of fat distribution.
All p-values are adjusted for gestational age at delivery, sex of the offspring, age at follow-up (for
skinfold thicknesses) and cell-types composition using ReFACTor. DNAm levels are shown between 0
and 1.
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2.3. Investigation of Placental DNAm Levels as Mediating Factor between Maternal Glycemia and Adiposity
Markers in Offspring
As maternal fasting glucose levels measured at the second trimester of pregnancy were associated
with cord blood leptinemia, we therefore tested whether they were also associated with placental
DNAm at the LEP gene locus and found a significant association with DNAm at cg15758240 (β = −0.01,
p = 0.04) (Table 4). These associations provided the ground to conduct mediation analysis. The results
support a causal relationship between maternal fasting glucose concentrations at second trimester of
pregnancy, placental DNAm at cg15758240, and cord blood leptinemia (mediation model p < 0.001;
Figure 2). Together, DNAm levels at cg15758240 and maternal glycemia explain 13.7% of cord blood
leptin levels variance at birth (p = 8.5 × 10−9), where DNAm alone mediates 0.8% of the effect. We did
not test mediation models with BMI-z and skinfold thickness measures as the outcome, since neither
the maternal glycemic profile nor the cord blood leptin levels were significantly associated with these
adiposity markers in children (data not shown).
Table 4. Associations between placental LEP DNA methylation levels and maternal glycemia
during pregnancy.
CpG Sites
Maternal Glucose 1 h
Post 50 g GCT at 1st
Trimester of Pregnancy
Maternal Fasting
Glucose at 2nd
Trimester of Pregnancy
Maternal Glucose 2 h
Post 75 g OGTT at 2nd
Trimester of Pregnancy
cg15758240 β < 0.001p = 0.74
β = −0.013
p = 0.04
β < 0.001
p = 0.21
cg05136031 β < 0.001p = 0.72
B < 0.001
p = 0.55
B < 0.001
p = 0.94
Significant results when p ≤ 0.05. Models were adjusted for maternal age and BMI at 1st trimester of pregnancy,
gestational age at delivery, sex of the child, age at follow-up, and placenta heterogeneity.
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3. Methods
3.1. Participants’ Selection from Gen3G Cohort
We selected participants from the Genetics of Glucose regulation in Gestation and Growth (Gen3G)
prospective birth cohort, which we have described previously [22]. Briefly, between January 2010 and
June 2013, we recruited women during the first trimester of pregnancy (n = 1024), with a follow-up
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through to delivery (n = 862) at the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Women less
than 18 years old at first visit, with multiple pregnancy, and pre-pregnancy diabetes were excluded.
For the current study, we also excluded participants when oral glucose tolerance test (OGTT) data were
incomplete, gestational age was <37 weeks (preterm birth), and placental samples as well as body mass
index z-scores (BMI-z) and skinfold thickness (ST) measures at 3-years-old were missing. A total of
262 mother–child dyads were retained for these analyses. The Chicoutimi Hospital Ethics Committee
approved the project, along with the ethical review board from the Centre hospitalier universitaire
de Sherbrooke. All women provided a written informed consent before their inclusion in the study,
in accordance with the Declaration of Helsinki.
3.2. Gen3G Follow-Up During Pregnancy
We collected both data and biological samples during pregnancy and at delivery. Data included
medical history, anthropometric measures, and maternal metabolic profile. We used the height and
weight to compute maternal body mass index (BMI), using standard formula (kg/m2). All mothers
performed a 75 g OGTT between gestational weeks 24 and 30, and gestational diabetes mellitus (GDM)
was diagnosed according to the Canadian Diabetes Association (CDA) criteria. Only 12 women with
GDM were included in the study, as they were treated with a diet only; we excluded women with GDM
treated with insulin, to avoid potential confounding impacts of insulin treatment on placenta biology.
3.3. Sampling and Measures at Birth
Within 30 min of delivery, well-trained staff collected cord blood and placental tissues, following
a standardized procedure. We collected placental biopsies (1 cm3) on the fetal side (i.e., 5 cm from
the umbilical cord insertion) and kept at −80 ◦C and in RNALater (Qiagen, USA) until nucleic acids
extractions. We measured neonatal leptin levels in cord blood, using ELISA, following manufacturer
instructions (B-Bridge International, USA).
3.4. Clinical Evaluation of Children
At the 3 years old follow-up, we collected medical history and anthropometric measures in
participating children. Briefly, we measured weight on a numeric balance and height, using a
stadiometer. We used these measures to compute the child’s BMI, which was used to assess the
BMI-z according to the WHO growth-chart reference for boys and girls (WHO Anthro software).
We measured ST in the subscapular (SS) and triceps (TR) regions to the nearest 0.1 mm, using a Holtain
skinfold caliper (Holtain Ltd., Crosswell, Wales), and computed the sum (ΣST = SS + TR) as a proxy of
overall adiposity, as well as the ratio (SS:TR) to reflect fat distribution in 262 participants. A total of 3
participants with extreme BMI (33.6 kg/m2) and skinfolds data (ΣST = 8.5 and 48.5 mm) were excluded
from the analyses, as they were >3 interquartile ranges (IQR) from the median values, and we were not
able to confirm the accuracy of the data.
3.5. DNA Extraction and Sample Preparation
We extracted DNA and RNA from placental biopsies using the All Prep DNA/RNA/Protein Mini
Kit (Qiagen, USA) following the manufacturer’s standard procedure and quantified double-strand
DNA using Quant-iT™ PicoGreen™ dsDNA Assay Kit (Qiagen, USA). We preformed sodium-bisulfite
conversion of DNA prior to the methylation analyses following recommendations of the EpiTect
Bisulfite Kit (Qiagen, USA).
3.6. Measurements of DNA Methylation
DNAm levels were quantified in placental tissues by using the Infinium MethylationEPIC
BeadChip (Illumina, USA), as described in our previous study [23]. To reduce potential technical
bias, we randomly allocated samples in plates and chips. DNAm data from the EPIC Array were
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implemented in minfi library in R, prior to the previously described preprocessing steps [23], which
include samples and probes quality controls (QC). We removed samples which failed the QC (n = 8),
were mismatched on genotype (n = 12) or sex (n = 1), and were technical duplicates (n = 10). We excluded
from the analysis probes weakly detected in ≥5% of placenta samples (n = 145 probes). We also
excluded probes on sex chromosomes (n = 19,536), non-CpG probes (n = 2839), SNPs-associated probes
(n = 77,787), probes affected by a single-base extension (n = 5435), or SNPs (n = 6075) at CpG sites with
a minor allele frequency ≥5% as well, as potential cross-hybridization probes (n = 34,088) [24].
We performed functional normalization that utilizes the control probes, to adjust for technical
variability [25]. We used regression on correlated probes (RCP), a method that leverages genomic
proximity, to adjust for technical bias from sample plate [26]. After QC, 25 CpG sites upstream or within
the LEP gene were identified and extracted from the dataset for further analysis, in order to focus on a
candidate gene approach. A total of 13 CpG sites (GRCh37/hg19; chr7: 127,876,829–127,894,849), with
mean DNAm levels between ≥5% and ≤95%, were included in the analyses, as CpG nearly entirely
methylated or unmethylated had been previously shown to have weak interindividual variability [27].
Mean DNAm levels were computed for CpGs showing DNAm correlation (r > 0.6) with each other
(Figure 3). These highly intercorrelated CpGs (n = 5) were analyzed as a region. DNAm outliers
were detected based on the IQR and removed from the analysis when they were >3 IQRs from the
median values.
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3.7. Statistical Analyses
The normality of the distributions was tested using the Shapiro–Wilk normality test, and
parametric tests were used when log transformation failed to adjust data distribution’s normality.
We then investigat d the association between offspring’s and mothers’ clinical characteristics (e.g.,
BMI, SF, a d glycemia), using Pearson’s correlation tests. Therefore, we assessed the asso iation
between placental LEP DNAm and cord blood lepti levels, to identify potentially functional CpG
sites. We test d ssociations by using the Pearson corr lation coefficient, and we selected only the
tatistically ignificant CpG sites after Bonferroni adjustment for multiple testing (0.05/9 CpGs (i.e.,
8 CpGs analyzed individually and 5 CpGs analyzed as a region) = significant at p < 0.006) for further
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analyses (i.e., associations with BMI z-scores and ST measures, using linear regressions). We included
gestational age at birth, child’s sex, and age at follow-up (for ST measures) as covariates in multivariate
linear regression models. In addition, we conducted an estimation of the placenta cellular heterogeneity
by using ReFACTor, which is a reference-free method, included in the models as the first 5 principal
components as it was sufficient to bring genomic inflation close to 1 [28]. We did not include maternal
smoking during pregnancy, as such a covariate is not associated with either DNAm at the LEP gene
locus or with childhood adiposity markers. We computed regression coefficients and p-values for each
CpG, to identify the DNAm sites associated with childhood adiposity, independently of these potential
confounding factors. We tested associations between significantly associated adiposity-CpG sites and
maternal glycemia during pregnancy, using linear regressions. We adjusted models for maternal age
and BMI at the 1st trimester of pregnancy, gestational age at delivery, sex of the child, and age at
follow-up and placenta heterogeneity.
3.8. Mediation Analysis
We conducted a mediation analysis, using maternal fasting glucose at the 2nd trimester of
pregnancy as the exposure, placental LEP DNAm levels at cg15758240 as mediators, and cord blood
leptinemia as outcome, using the PROCESS procedure created by Hayes, as implemented in the SPSS
statistical software (v22.0.0, IBM, USA) [29]. We used 5000 bootstraps to generate estimates, and results
were considered significant at p ≤ 0.05 [30]. We adjusted the mediation model for gestational age at
delivery, sex of the child, maternal age, BMI at 1st trimester of pregnancy, and placenta heterogeneity
as covariates. We performed all statistical analyses by using SPSS software.
4. Discussion
Accumulating evidence supports that adiposity may be epigenetically regulated and programmed
in utero [31–33]. However, the biological pathways involved, as well as the influence of the various
intrauterine exposures (e.g., maternal obesity and GDM) on epivariations “programming” are yet
to be identified. In this study, we provide novel supportive evidence that placental DNAm at the
LEP gene locus may mediate the association between maternal hyperglycemia and higher cord blood
leptin levels, a proxy measure for adiposity at birth, as leptin in cord blood may reflect not only
placenta production, but also fetal adipose tissue [18]. To the best of our knowledge, there are only
few longitudinal studies, including ours, supporting that epigenetic variations in response to an early
exposure to maternal hyperglycemia might include dysregulation of the leptin pathway, potentially
leading to a pathophysiological reprogramming of the metabolism and obesity [34].
We previously used a Mendelian randomization approach, using cord blood DNAm levels at the
cg12083122 (located in the first intronic region of the LEP gene), to investigate the causality link between
DNAm variations at the LEP gene locus and cord blood leptin levels [21]. In our previous study, we
showed that an exposure to maternal hyperglycemia during pregnancy likely modulated neonatal
leptinemia, partially through changes in cord blood LEP DNAm levels. Interestingly, using placenta
and a statistical mediation analysis approach created by Hayes [29], we herein provide additional
evidence that a higher maternal glycemia during pregnancy increases cord blood leptin levels, partially
through a decrease in leptin DNAm levels in placenta. Our results are consistent with our previous
work, using both alternative tissue (i.e., placenta) and CpG site (cg12083122 was excluded from our
current analysis, as its mean DNAm levels >95% (97% ± 1%) in placenta tissue) [21].
The cg15758240 provided the more convincing results for a mediating role between maternal
glucose levels impacting placental LEP DNAm levels, which then contribute to cord blood leptin level
regulation and are associated with skinfold thickness at 3-years-old. This CpG is located upstream
(−4501 bp) the LEP gene (whereas the cg012083122 was located in first intron, +8224 bp), nearby a DNase
hypersensitivity cluster (−176 bp) and directly within a region susceptible to histone modifications
(H3K27ac mark), an epigenetic modification highly suspected to regulate gene expression through the
chromatin remodeling (Supplementary Figure S1) [35]. This CpG site has recently been characterized
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as an LEP interaction region (chr7: 127,854,840–127,881,330). Also based on ENCODE data, cg15758240
is in the vicinity of a number of transcription factor binding sites, including YY1 (−99 bp), CEBPB
(−144 bp), USF1 (−164 bp), STAT3 (−184 bp), and GATA2 (−204 bp), which has been previously linked
to obesity [36–40], suggesting that cg15758240 is located within a genomic region relevant for both fat
accretion and transcriptional regulation activity. Hence, we herein add to the current evidence that the
harmful effects of maternal hyperglycemia on offspring adiposity and obesity risk is likely to include
epigenetic dysregulation of the leptin gene pathway.
So far, only few studies investigated the epigenetic regulation of the leptin pathway in humans
and its impact on childhood adiposity. Although these are mainly cross-sectional studies covering
different childhood periods and phenotypes, they showed that whole blood DNAm levels within
the leptin gene promoter boundaries were associated with BMI in infancy, along with obesity and
insulin resistance in later life [12–14,41]. As an example, Tobi et al. reported LEP DNAm variations
in blood cells collected in 60-year-old men that were exposed to famine periods during in utero
development [42]. Interestingly, it was previously shown that LEP blood DNAm was lower in obese
and insulin-resistant adolescents [12–14]. These results, combined with those of Obermann-Borst
and colleagues who reported a decrease in the DNAm levels of the LEP gene in whole blood cells
collected at 17 months in children, in association with increased BMI and birthweight, suggest that the
LEP DNAm variations could be involved in fetal programming of growth and fat accretion in early
childhood [41]. In addition, we and others have previously reported that fetal leptin gene expression
and protein levels might be regulated by LEP promoter DNAm adaptations to maternal glycemic
variations and other metabolic disorders during pregnancy [43–46]. These studies have better defined
the role of epigenetic modifications in the regulation of the leptin gene and highlighted the fetal origins
of these epivariations, although none of them were performed in prospective cohorts and they all
focused on the LEP promoter region.
In our study, placental DNAm levels at the LEP gene locus were inversely correlated with both
leptin levels at birth (a proxy of neonatal adiposity) and adiposity at 3-years-old, where the strongest
association with the latter outcome was found with the skinfold thickness ratio (SS:TR), a marker
of fat distribution. More precisely, our results showed that lower placental DNAm levels upstream
the LEP gene (cg15758240) are associated with the distribution of fat depot in early childhood. Even
if this association was modest, these results support that fat distribution might involve early life
establishment of epigenetic marks.
In addition, our findings underpin DNAm as a plausible molecular mechanism and the LEP gene
locus as a determinant of fat accretion and distribution in early childhood, which is in accordance with
a previous study supporting how fat distribution (i.e., gynoid vs. android) might be determined before
the age of seven [47]. In addition, our association between LEP DNAm and maternal hyperglycemia as
a marker of childhood fat distribution seemed to be independent of neonatal leptinemia. Interestingly,
it was previously reported that neonatal leptin levels might be associated with growth trajectories and
childhood BMI [48,49], but other studies showed that both lower and higher leptin levels are associated
with weight gain [50–57]. Nevertheless, although the association between neonatal leptinemia
and childhood growth and adiposity (e.g., weight gain, BMI, and/or obesity) has been previously
reported [48–58], the impacts of altered neonatal leptin levels on fat distribution during childhood still
need to be clearly defined.
Strengths and Limitations
We reported results from a longitudinal study with placenta biopsies combined with a
gold-standard technology (i.e., MethylationEPIC array), which provided strong evidence that maternal
hyperglycemia contributes to epigenetic dysregulation of neonatal leptinemia, and this is clearly
among the strengths of our study. However, we did not show a clear impact on childhood fat accretion
and distribution at 3 years of age, maybe due to a lack of power. Consistent with our hypothesis,
the assessment of DNAm in adipose tissue at birth and at 3-years-old, for example, would have
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been clear, but was not feasible for obvious ethical reasons. Still, the investigation of placenta is
nonetheless interesting, as this tissue is involved in the secretion of leptin but could also reflect the
methylation pattern of other tissues/cell types of common developmental origin [18,59]. Furthermore,
the measurement of circulating leptin levels at three years would have made it possible to document
the potential temporal stability of the reported DNAm marks and to determine to what extent these
fetal origin marks could have an impact later in life.
5. Conclusions
In this study, we provide novel evidence supporting the mediating effects of placental LEP
DNAm dysregulation in response to maternal hyperglycemia during pregnancy on neonatal leptin
levels, a proxy for adiposity at birth. Our findings highlight the implication of DNAm as a potential
mechanism of fetal programming of adiposity, which might include epigenetic alterations of the
leptin gene. Although we also report associations between placental DNAm at the LEP gene locus
and adiposity at 3-years-old, the causal relationship using mediation analysis could not be tested.
Still, these findings underscore the need to look further into the fetal epigenetic programming of
childhood obesity.
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Author Contributions: V.G.-O. performed the data collection, performed the statistical analyses, and wrote the
manuscript. E.B., K.T., and C.-A.F. helped in data collection. A.C. participated in the statistical analyses. R.G.,
P.P., and M.-F.H. participated in the conception of the study design and thoroughly revised the manuscript. L.B.
supervised all steps of the study and participated in manuscript redaction and revision. All authors have read and
agreed to the published version of the manuscript.
Funding: This project was supported by American Diabetes Association accelerator award #1-15-ACE-26 (M.F.H),
Fonds de recherche du Québec en santé (FRSQ) #20697 (M.F.H), Canadian Institute of Health Research #MOP
115071 (M.F.H), and Diabète Québec grants (PP and LB).
Acknowledgments: LB is a senior research scholar from the Fond de la recherche du Québec en santé (FRQS).
MFH is also supported by a Canadian Diabetes Association clinical scientist award. LB, MFH, and PP are members
of the FRQS-funded Centre de recherche du CHUS (affiliated to the Centre hospitalier universitaire de Sherbrooke).
VGO received a Doctoral research award from the FRQS in partnership with the Foundation of Stars, while EB
and KT had a Master degree research award from the FRQS.
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
BMI-z Body mass index z-scores
DNAm DNA methylation
CpG 5′-C-phosphate-G-3′
DNMT DNA methyltransferase
DOHaD Developmental origins of health and diseases
GCT Glucose challenge test
GDM Gestational diabetes mellitus
Gen3G
Genetics of Glucose regulation in Gestation and
Growth
IQR Interquartile range
LEP Leptin
OGTT Oral glucose tolerance test
RCP Regression on correlated probes
RIN RNA integrity number
SS Suprascapular
ST Skinfold Thickness
TR Tricipital
Int. J. Mol. Sci. 2020, 21, 329 11 of 13
References
1. WHO. Report of the Commission on Ending Childhood Obesity: Implementation Plan: Executive Summary; World
Health Organization: Geneva, Switzerland, 2017.
2. Sahoo, K.; Sahoo, B.; Choudhury, A.K.; Sofi, N.Y.; Kumar, R.; Bhadoria, A.S. Childhood obesity: Causes and
consequences. J. Fam. Med. Prim. Care 2015, 4, 187–192.
3. Deshmukh-Taskar, P.; Nicklas, T.A.; Morales, M.; Yang, S.J.; Zakeri, I.; Berenson, G.S. Tracking of overweight
status from childhood to young adulthood: The Bogalusa Heart Study. Eur. J. Clin. Nutr. 2006, 60, 48–57.
[CrossRef] [PubMed]
4. Ma, R.C.W.; Popkin, B.M. Intergenerational diabetes and obesity—A cycle to break? PLoS Med. 2017, 14,
e1002415. [CrossRef] [PubMed]
5. Barker, D.J.; Osmond, C.; Kajantie, E.; Eriksson, J.G. Growth and chronic disease: Findings in the Helsinki
Birth Cohort. Ann. Hum. Biol. 2009, 36, 445–458. [CrossRef]
6. Barker, D.J. The developmental origins of chronic adult disease. Acta Paediatr. Suppl. 2004, 93, 26–33.
[CrossRef]
7. Barker, D.J. The developmental origins of adult disease. J. Am. Coll. Nutr. 2004, 23, 588S–595S. [CrossRef]
8. Barker, D.J. Developmental origins of adult health and disease. J. Epidemiol. Community Health 2004, 58,
114–115. [CrossRef]
9. Barker, D.J. The developmental origins of insulin resistance. Horm. Res. 2005, 64, 2–7. [CrossRef]
10. Foley, D.L.; Craig, J.M.; Morley, R.; Olsson, C.A.; Dwyer, T.; Smith, K.; Saffery, R. Prospects for epigenetic
epidemiology. Am. J. Epidemiol. 2009, 169, 389–400. [CrossRef]
11. Dolinoy, D.C.; Weidman, J.R.; Waterland, R.A.; Jirtle, R.L. Maternal genistein alters coat color and protects
Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 2006, 114,
567–572. [CrossRef]
12. Garcia-Cardona, M.C.; Huang, F.; Garcia-Vivas, J.M.; Lopez-Camarillo, C.; Del Rio Navarro, B.E.; Navarro
Olivos, E.; Hong-Chong, E.; Bolanos-Jimenez, F.; Marchat, L.A. DNA methylation of leptin and adiponectin
promoters in children is reduced by the combined presence of obesity and insulin resistance. Int. J. Obes.
2014, 38, 1457–1465. [CrossRef] [PubMed]
13. Xia, L.; Wang, C.; Lu, Y.; Fan, C.; Ding, X.; Fu, H.; Qi, K. Time-specific changes in DNA methyltransferases
associated with the leptin promoter during the development of obesity. Nutr. Hosp. 2014, 30, 1248–1255.
[PubMed]
14. Yang, M.; Sun, J.Z.; Sun, Y.L.; You, W.; Dai, J.; Li, G.S. Association between leptin gene promoter methylation
and type 2 diabetes mellitus (Article in Chinese). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012, 29, 474–477.
[PubMed]
15. Maccani, M.A.; Marsit, C.J. Epigenetics in the placenta. Am. J. Reprod. Immunol. 2009, 62, 78–89. [CrossRef]
[PubMed]
16. Jansson, T.; Powell, T.L. Role of the placenta in fetal programming: Underlying mechanisms and potential
interventional approaches. Clin. Sci. 2007, 113, 1–13. [CrossRef]
17. Sood, R.; Zehnder, J.L.; Druzin, M.L.; Brown, P.O. Gene expression patterns in human placenta. Proc. Natl.
Acad. Sci. USA 2006, 103, 5478–5483. [CrossRef]
18. Zhou, Y.; Rui, L. Leptin signaling and leptin resistance. Front. Med. 2013, 7, 207–222. [CrossRef]
19. Morris, D.L.; Cho, K.W.; Rui, L. Critical role of the Src homology 2 (SH2) domain of neuronal SH2B1 in the
regulation of body weight and glucose homeostasis in mice. Endocrinology 2010, 151, 3643–3651. [CrossRef]
20. Coppari, R.; Bjorbaek, C. Leptin revisited: Its mechanism of action and potential for treating diabetes.
Nat. Rev. Drug Discov. 2012, 11, 692–708. [CrossRef]
21. Allard, C.; Desgagne, V.; Patenaude, J.; Lacroix, M.; Guillemette, L.; Battista, M.C.; Doyon, M.; Menard, J.;
Ardilouze, J.L.; Perron, P.; et al. Mendelian randomization supports causality between maternal
hyperglycemia and epigenetic regulation of leptin gene in newborns. Epigenetics 2015, 10, 342–351. [CrossRef]
22. Guillemette, L.; Allard, C.; Lacroix, M.; Patenaude, J.; Battista, M.C.; Doyon, M.; Moreau, J.; Menard, J.;
Bouchard, L.; Ardilouze, J.L.; et al. Genetics of Glucose regulation in Gestation and Growth (Gen3G):
A prospective prebirth cohort of mother-child pairs in Sherbrooke, Canada. BMJ Open 2016, 6, e010031.
[CrossRef]
Int. J. Mol. Sci. 2020, 21, 329 12 of 13
23. Cardenas, A.; Gagne-Ouellet, V.; Allard, C.; Brisson, D.; Perron, P.; Bouchard, L.; Hivert, M.F. Placental
DNA Methylation Adaptation to Maternal Glycemic Response in Pregnancy. Diabetes 2018, 67, 1673–1683.
[CrossRef] [PubMed]
24. Pidsley, R.; Zotenko, E.; Peters, T.J.; Lawrence, M.G.; Risbridger, G.P.; Molloy, P.; Van Djik, S.; Muhlhausler, B.;
Stirzaker, C.; Clark, S.J. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for
whole-genome DNA methylation profiling. Genome Biol. 2016, 17, 208. [CrossRef] [PubMed]
25. Fortin, J.P.; Labbe, A.; Lemire, M.; Zanke, B.W.; Hudson, T.J.; Fertig, E.J.; Greenwood, C.M.; Hansen, K.D.
Functional normalization of 450k methylation array data improves replication in large cancer studies.
Genome Biol. 2014, 15, 503. [CrossRef] [PubMed]
26. Johnson, W.E.; Li, C.; Rabinovic, A. Adjusting batch effects in microarray expression data using empirical
Bayes methods. Biostatistics 2007, 8, 118–127. [CrossRef] [PubMed]
27. Logue, M.W.; Smith, A.K.; Wolf, E.J.; Maniates, H.; Stone, A.; Schichman, S.A.; McGlinchey, R.E.; Milberg, W.;
Miller, M.W. The correlation of methylation levels measured using Illumina 450K and EPIC BeadChips in
blood samples. Epigenomics 2017, 9, 1363–1371. [CrossRef] [PubMed]
28. Rahmani, E.; Zaitlen, N.; Baran, Y.; Eng, C.; Hu, D.; Galanter, J.; Oh, S.; Burchard, E.G.; Eskin, E.; Zou, J.; et al.
Sparse PCA corrects for cell type heterogeneity in epigenome-wide association studies. Nat. Methods 2016,
13, 443–445. [CrossRef]
29. Hayes, A.F.; Rockwood, N.J. Regression-based statistical mediation and moderation analysis in clinical
research: Observations, recommendations, and implementation. Behav. Res. Ther. 2017, 98, 39–57. [CrossRef]
30. Preacher, K.J.; Hayes, A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects
in multiple mediator models. Behav. Res. Methods 2008, 40, 879–891. [CrossRef]
31. Fernandez-Twinn, D.S.; Hjort, L.; Novakovic, B.; Ozanne, S.E.; Saffery, R. Intrauterine programming of
obesity and type 2 diabetes. Diabetologia 2019, 62, 1789–1801. [CrossRef]
32. Goyal, D.; Limesand, S.W.; Goyal, R. Epigenetic responses and the developmental origins of health and
disease. J. Endocrinol. 2019, 242, T105–T119. [CrossRef] [PubMed]
33. Lillycrop, K.A.; Burdge, G.C. Epigenetic changes in early life and future risk of obesity. Int. J. Obes. 2011, 35,
72–83. [CrossRef] [PubMed]
34. Ling, C.; Ronn, T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019, 29, 1028–1044.
[CrossRef] [PubMed]
35. Calo, E.; Wysocka, J. Modification of enhancer chromatin: What, how, and why? Mol. Cell 2013, 49, 825–837.
[CrossRef] [PubMed]
36. Verdeguer, F.; Soustek, M.S.; Hatting, M.; Blattler, S.M.; McDonald, D.; Barrow, J.J.; Puigserver, P. Brown
Adipose YY1 Deficiency Activates Expression of Secreted Proteins Linked to Energy Expenditure and
Prevents Diet-Induced Obesity. Mol. Cell. Biol. 2015, 36, 184–196. [CrossRef] [PubMed]
37. Pan, D.Z.; Garske, K.M.; Alvarez, M.; Bhagat, Y.V.; Boocock, J.; Nikkola, E.; Miao, Z.; Raulerson, C.K.;
Cantor, R.M.; Civelek, M.; et al. Integration of human adipocyte chromosomal interactions with adipose
gene expression prioritizes obesity-related genes from GWAS. Nat. Commun. 2018, 9, 1512. [CrossRef]
38. Laurila, P.P.; Soronen, J.; Kooijman, S.; Forsstrom, S.; Boon, M.R.; Surakka, I.; Kaiharju, E.; Coomans, C.P.;
Van Den Berg, S.A.; Autio, A.; et al. USF1 deficiency activates brown adipose tissue and improves
cardiometabolic health. Sci. Transl. Med. 2016, 8, 323ra13. [CrossRef]
39. Liu, Y.; Xu, D.; Yin, C.; Wang, S.; Wang, M.; Xiao, Y. IL-10/STAT3 is reduced in childhood obesity with
hypertriglyceridemia and is related to triglyceride level in diet-induced obese rats. BMC Endocr. Disord.
2018, 18, 39. [CrossRef]
40. Tong, Q.; Dalgin, G.; Xu, H.; Ting, C.N.; Leiden, J.M.; Hotamisligil, G.S. Function of GATA transcription
factors in preadipocyte-adipocyte transition. Science 2000, 290, 134–138. [CrossRef]
41. Obermann-Borst, S.A.; Eilers, P.H.; Tobi, E.W.; de Jong, F.H.; Slagboom, P.E.; Heijmans, B.T.;
Steegers-Theunissen, R.P. Duration of breastfeeding and gender are associated with methylation of the
LEPTIN gene in very young children. Pediatr. Res. 2013, 74, 344–349. [CrossRef]
42. Tobi, E.W.; Lumey, L.H.; Talens, R.P.; Kremer, D.; Putter, H.; Stein, A.D.; Slagboom, P.E.; Heijmans, B.T.
DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific.
Hum. Mol. Genet. 2009, 18, 4046–4053. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 329 13 of 13
43. Lesseur, C.; Armstrong, D.A.; Paquette, A.G.; Li, Z.; Padbury, J.F.; Marsit, C.J. Maternal obesity and gestational
diabetes are associated with placental leptin DNA methylation. Am. J. Obstet. Gynecol. 2014, 211, 654-e1.
[CrossRef] [PubMed]
44. Bouchard, L.; Thibault, S.; Guay, S.P.; Santure, M.; Monpetit, A.; St-Pierre, J.; Perron, P.; Brisson, D. Leptin gene
epigenetic adaptation to impaired glucose metabolism during pregnancy. Diabetes Care 2010, 33, 2436–2441.
[CrossRef] [PubMed]
45. Hogg, K.; Blair, J.D.; von Dadelszen, P.; Robinson, W.P. Hypomethylation of the LEP gene in placenta and
elevated maternal leptin concentration in early onset pre-eclampsia. Mol. Cell. Endocrinol. 2013, 367, 64–73.
[CrossRef] [PubMed]
46. Lesseur, C.; Armstrong, D.A.; Paquette, A.G.; Koestler, D.C.; Padbury, J.F.; Marsit, C.J. Tissue-specific Leptin
promoter DNA methylation is associated with maternal and infant perinatal factors. Mol. Cell. Endocrinol.
2013, 381, 160–167. [CrossRef] [PubMed]
47. Chrzanowska, M.; Suder, A.; Kruszelnicki, P. Tracking and risk of abdominal obesity in the adolescence
period in children aged 7–15. The Cracow Longitudinal Growth Study. Am. J. Hum. Biol. 2012, 24, 62–67.
[CrossRef] [PubMed]
48. Buck, C.O.; Eliot, M.N.; Kelsey, K.T.; Chen, A.; Kalkwarf, H.; Lanphear, B.P.; Braun, J.M. Neonatal
Adipocytokines and Longitudinal Patterns of Childhood Growth. Obesity 2019, 27, 1323–1330. [CrossRef]
49. Yeung, E.H.; Sundaram, R.; Xie, Y.; Lawrence, D.A. Newborn adipokines and early childhood growth. Pediatr.
Obes. 2018, 13, 505–513. [CrossRef]
50. Chessler, S.D.; Fujimoto, W.Y.; Shofer, J.B.; Boyko, E.J.; Weigle, D.S. Increased plasma leptin levels are
associated with fat accumulation in Japanese Americans. Diabetes 1998, 47, 239–243. [CrossRef]
51. Chu, N.F.; Spiegelman, D.; Yu, J.; Rifai, N.; Hotamisligil, G.S.; Rimm, E.B. Plasma leptin concentrations and
four-year weight gain among US men. Int. J. Obes. 2001, 25, 346–353. [CrossRef]
52. Lissner, L.; Karlsson, C.; Lindroos, A.K.; Sjostrom, L.; Carlsson, B.; Carlsson, L.; Bengtsson, C. Birth weight,
adulthood BMI, and subsequent weight gain in relation to leptin levels in Swedish women. Obes. Res. 1999,
7, 150–154. [CrossRef] [PubMed]
53. Ahmed, M.L.; Ong, K.K.; Morrell, D.J.; Cox, L.; Drayer, N.; Perry, L.; Preece, M.A.; Dunger, D.B. Longitudinal
study of leptin concentrations during puberty: Sex differences and relationship to changes in body
composition. J. Clin. Endocrinol. Metab. 1999, 84, 899–905. [CrossRef] [PubMed]
54. Byrnes, S.E.; Baur, L.A.; Bermingham, M.; Brock, K.; Steinbeck, K. Leptin and total cholesterol are predictors
of weight gain in pre-pubertal children. Int. J. Obes. 1999, 23, 146–150. [CrossRef] [PubMed]
55. Fleisch, A.F.; Agarwal, N.; Roberts, M.D.; Han, J.C.; Theim, K.R.; Vexler, A.; Troendle, J.; Yanovski, S.Z.;
Yanovski, J.A. Influence of serum leptin on weight and body fat growth in children at high risk for adult
obesity. J. Clin. Endocrinol. Metab. 2007, 92, 948–954. [CrossRef] [PubMed]
56. Johnson, M.S.; Huang, T.T.; Figueroa-Colon, R.; Dwyer, J.H.; Goran, M.I. Influence of leptin on changes in
body fat during growth in African American and white children. Obes. Res. 2001, 9, 593–598. [CrossRef]
[PubMed]
57. Savoye, M.; Dziura, J.; Castle, J.; DiPietro, L.; Tamborlane, W.V.; Caprio, S. Importance of plasma leptin in
predicting future weight gain in obese children: A two-and-a-half-year longitudinal study. Int. J. Obes. 2002,
26, 942–946. [CrossRef]
58. Li, L.J.; Rifas-Shiman, S.L.; Aris, I.M.; Mantzoros, C.; Hivert, M.F.; Oken, E. Leptin trajectories from birth to
mid-childhood and cardio-metabolic health in early adolescence. Metabolism 2019, 91, 30–38. [CrossRef]
59. Christensen, J.L.; Wright, D.E.; Wagers, A.J.; Weissman, I.L. Circulation and chemotaxis of fetal hematopoietic
stem cells. PLoS Biol. 2004, 2, E75. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
